Compare KKR & Co Inc (KKR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Organon & Co. Common Stock — how do they compare? KKR & Co Inc trades at $86.13 (market cap $78.24B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: KKR & Co Inc is far larger — about 21.6× Organon & Co. Common Stock's market cap, and KKR & Co Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Organon & Co. Common Stock for 0 Days on average.
| KKR | OGN | |
|---|---|---|
Market Cap | $78.24B | $3.62B |
Volume | 9,217,096 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $142.75 | $13.81 |
52-Week Low | $83.88 | $5.70 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $795.68M | $11.04B |
Dividend Yield | 0.89% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $87.16, down 4.75% today, amid bearish technical signals despite strong analyst support. The stock shows mixed fundamentals with a P/E of 27.85 and recent earnings beats, though Q4 2025 missed expectations. Recent corporate activity includes strategic investments in global ventures and a $0.20 dividend declaration. Cash flow trends indicate volatile operational performance, with 2025 net cash flow at $1.78 billion.
Outlook remains cautiously optimistic given 88.9% analyst buy ratings and a $123.20 price target, representing 41% upside. Key risks include execution of recent acquisitions and market sensitivity to private equity cycles. The current dip may present a buying opportunity for long-term investors seeking exposure to alternative asset management growth.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
